Regulatory Effect and Mechanism of Erythroblastic Island Macrophages on Anemia in Patients with Newly Diagnosed Multiple Myeloma

被引:0
|
作者
Huang, Hao [1 ,2 ]
Yu, Peng-Yang [1 ,2 ]
Wei, Chen [2 ,3 ]
Li, Yang-Wei [2 ,4 ]
Liang, Li-Jie [1 ,2 ]
Liu, Yu-Zhang [1 ,2 ]
Liu, Li-Na [1 ,2 ]
Fang, Bai-Jun [1 ,2 ]
Wang, Yao-Mei [1 ,2 ]
机构
[1] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Henan, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Henan, Peoples R China
[3] Zhengzhou Univ, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Henan, Peoples R China
[4] Zhengzhou Univ, Cent Lab, Affiliated Canc Hosp, Zhengzhou, Henan, Peoples R China
基金
中国国家自然科学基金;
关键词
anemia; central macrophages; erythroblastic islands; erythropoiesis; multiple myeloma; ERYTHROID-DIFFERENTIATION; PLASMA-CELLS; ALPHA; ERYTHROPOIESIS; PROTEIN; PROLIFERATION; EXPRESSION; MATURATION; HEPCIDIN; CRITERIA;
D O I
10.2147/JIR.S413044
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To examine the clinical characteristics and anemia-related factors in patients with newly diagnosed multiple myeloma (NDMM), as well as the effect and mechanism of erythroblastic islands (EBIs) and EBI macrophages in NDMM patients with anemia. Methods: We collected and analyzed clinical data to find anemia-related factors. Using flow cytometry, the numbers and ratios of erythroblasts and EBI macrophages were determined. RNA sequencing (RNA-seq) was used to determine the differences of EBI macrophages in NDMM patients with or without anemia. Results: Based on the clinical characteristics of NDMM patients with anemia, MCV, abnormal levels of albumin, osteolytic lesions, and Durie-Salmon (DS) stage are risk factors for anemia. Patients with anemia have fewer erythroblasts, erythroblastic islands (EBIs), and EBI macrophages in their bone marrow than patients without anemia. RNA-seq analysis of EBI macrophages from the bone marrow of patients with and without anemia revealed that macrophages from patients with anemia are impaired and tend to promote the production of interleukin-6, which has been demonstrated to be an essential survival factor of myeloma cells and protects them from apoptosis. Conclusion: In NDMM patients with anemia, EBI macrophages are impaired, which causes anemia in those patients. Our finding highlights the significance of EBI macrophages in anemia in NDMM patients and provides a new strategy for recovery from anemia in these patients.
引用
收藏
页码:2585 / 2594
页数:10
相关论文
共 50 条
  • [1] The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment
    Banaszkiewicz, Malgorzata
    Malyszko, Jolanta
    Batko, Krzysztof
    Koc-Zorawska, Ewa
    Zorawski, Marcin
    Dumnicka, Paulina
    Jurczyszyn, Artur
    Woziwodzka, Karolina
    Maleszka, Aleksandra
    Krzanowski, Marcin
    Krasniak, Andrzej
    Drozdz, Ryszard
    Krzanowska, Katarzyna
    MEDICINA-LITHUANIA, 2022, 58 (03):
  • [2] Management of Newly Diagnosed Elderly Multiple Myeloma Patients
    Crystal Antoine-Pepeljugoski
    Marc Justin Braunstein
    Current Oncology Reports, 2019, 21
  • [3] Management of Newly Diagnosed Elderly Multiple Myeloma Patients
    Antoine-Pepeljugoski, Crystal
    Braunstein, Marc Justin
    CURRENT ONCOLOGY REPORTS, 2019, 21 (07)
  • [4] Frontline therapy for newly diagnosed patients with multiple myeloma
    Jung, Sung-Hoon
    Jo, Jae-Cheol
    Song, Ga-Young
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Ahn, Jae-Sook
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BLOOD RESEARCH, 2020, 55 : 37 - 42
  • [5] Treatment for patients with newly diagnosed multiple myeloma in 2015
    Mateos, Maria-Victoria
    Ocio, Enrique M.
    Paiva, Bruno
    Rosinol, Laura
    Martinez-Lopez, Joaquin
    Blade, Joan
    Lahuerta, Juan-Jose
    Garcia-Sanz, Ramon
    San Miguel, Jesus F.
    BLOOD REVIEWS, 2015, 29 (06) : 387 - 403
  • [6] Substratification of patients with newly diagnosed standard-risk multiple myeloma
    Binder, Moritz
    Rajkumar, S. Vincent
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Hwa, Yi L.
    Zeldenrust, Steven R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Kapoor, Prashant
    Go, Ronald S.
    Gonsalves, Wilson I.
    Kyle, Robert A.
    Kumar, Shaji K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (02) : 254 - 260
  • [7] Underweight as a risk factor of mortality in patients with newly diagnosed multiple myeloma
    Tsai, Chun-Kuang
    Yeh, Chiu-Mei
    Hsu, Te-Lin
    Li, Chia-Ju
    Tin, Chian
    Hsiao, Liang-Tsai
    Liu, Yao-Chung
    Wang, Hao-Yuan
    Ko, Po-Shen
    Chen, Po-Min
    Liu, Jin-Hwang
    Gau, Jyh-Pyng
    Liu, Chia-Jen
    SUPPORTIVE CARE IN CANCER, 2021, 29 (07) : 3991 - 3999
  • [8] Modern treatments and future directions for newly diagnosed multiple myeloma patients
    Lu, Sydney X.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2020, 33 (01)
  • [9] Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma
    Suzuki, Kazuhito
    Yano, Shingo
    Nishiwaki, Kaichi
    Sano, Koji
    Shimada, Takaki
    Yahagi, Yuichi
    Ogasawara, Yoji
    Sugiyama, Katsuki
    Takahara, Shinobu
    Saito, Takeshi
    Kasama, Kinuyo
    Minami, Jiro
    Yokoyama, Hiroki
    Kamiyama, Yutaro
    Katsube, Atsushi
    Masuoka, Hidekazu
    Katori, Mitsuji
    Machishima, Tomohito
    Ouchi, Aya
    Dobashi, Nobuaki
    Kaito, Ken
    Usui, Noriko
    Aiba, Keisuke
    CANCER MEDICINE, 2016, 5 (11): : 3051 - 3058
  • [10] Newly diagnosed multiple myeloma.
    Weber D.M.
    Current Treatment Options in Oncology, 2002, 3 (3) : 235 - 245